These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6423391)

  • 1. Failure of 2-mercaptoethane sulphonate sodium (mesna) to protect against ifosfamide nephrotoxicity.
    Sangster G; Kaye SB; Calman KC; Dalton JF
    Eur J Cancer Clin Oncol; 1984 Mar; 20(3):435-6. PubMed ID: 6423391
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
    Araujo CE; Tessler J
    Eur J Cancer Clin Oncol; 1983 Feb; 19(2):195-201. PubMed ID: 6402369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity.
    Hilgard P; Burkert H
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1451-2. PubMed ID: 6437825
    [No Abstract]   [Full Text] [Related]  

  • 5. Does 2-mercaptoethane sulphonate (mesna) prevent cyclophosphamide and azathioprine induced immunosuppression? In vitro studies.
    Al-Safi SA; Maddocks JL
    Br J Clin Pharmacol; 1986 Mar; 21(3):267-70. PubMed ID: 2938613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():1-192. PubMed ID: 6414687
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Czownicki Z; Utracka-Hutka B
    Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
    [No Abstract]   [Full Text] [Related]  

  • 8. Ifosfamide, mesna, and encephalopathy.
    Lancet; 1985 Jun; 1(8442):1398-9. PubMed ID: 2861351
    [No Abstract]   [Full Text] [Related]  

  • 9. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
    Falkson G; Van Dyk JJ; Stapelberg R; Falkson HC
    Cancer Chemother Pharmacol; 1982; 9(2):81-4. PubMed ID: 6816479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas.
    Ajani JA; Abbruzzese JL; Goudeau P; Faintuch JS; Yeomans AC; Boman BM; Nicaise C; Levin B
    J Clin Oncol; 1988 Nov; 6(11):1703-7. PubMed ID: 3141592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
    Bryant BM; Jarman M; Ford HT; Smith IE
    Lancet; 1980 Sep; 2(8196):657-9. PubMed ID: 6106781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M; Fujiwara F; Todo S; Morioka Y; Imashuku S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
    Brock N; Stekar J
    Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide and ifosfamide: role of uroprotective agents.
    Williams SD; Munshi N; Einhorn LH; Loehrer PJ
    Cancer Invest; 1990; 8(2):269. PubMed ID: 2119246
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical overview of mesna.
    Burkert H
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():175-81. PubMed ID: 6414692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encephalopathy associated with ifosphamide/mesna therapy.
    Meanwell CA; Blake AE; Latief TN; Blackledge G; Mould JJ; Blake DR; Shaw IC; Honigsberger L; Spooner D; Williams AC
    Lancet; 1985 Feb; 1(8425):406-7. PubMed ID: 2857462
    [No Abstract]   [Full Text] [Related]  

  • 17. [Antidote against the urotoxic effects of the oxazaphorine derivatives cyclophosphamide, ifosfamide and trofosfamide].
    Brock N; Stekar J; Pohl J
    Naturwissenschaften; 1979 Jan; 66(1):60-1. PubMed ID: 106307
    [No Abstract]   [Full Text] [Related]  

  • 18. Ifosfamide/mesa and encephalopathy.
    Cantwell BM; Harris AL
    Lancet; 1985 Mar; 1(8431):752. PubMed ID: 2858016
    [No Abstract]   [Full Text] [Related]  

  • 19. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
    Brock N
    Recent Results Cancer Res; 1980; 74():270-8. PubMed ID: 6777836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Marti C; Steiner R; Viollier AF
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1885-7. PubMed ID: 119317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.